Benzinga | Dec 8, 2021 09:56AM EST

Virpax Posts Toxicology, Pharmacokinetic Data For Pain Med Epoladerm

* Virpax Pharmaceuticals Inc (NASDAQ:VRPX) reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with osteoarthritis of the knee.

* Charles River Laboratories International Inc (NYSE:CRL), CRO engaged by Virpax, completed the study in minipigs as part of the required Investigational New Drug Application enabling trials.

* Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs, and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed.

* All Epoladerm treated animals had plasma levels of Epoladerm confirming transdermal absorption.

* The maximum plasma concentration (Cmax) was reached at 4 hours post-dose, and plasma Epoladerm remained at 24-hour post-dose for all animals.

* Virpax Pharmaceuticals is developing Epoladerm (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film.

* Price Action: VRPX shares are up 1.48% at $4.11 during the market session on the last check Wednesday.